Stanford, Stanford, CA
Ishan Paranjpe , Pranav Sharma , Chen Wei , Vikram Puram , Samir Kamat , Ali Raza Khaki
Background: Following the 2021 Hospital Price Transparency Final Rule, US hospitals were mandated to publish their insurer-negotiated prices. We identified factors contributing to price variability of colorectal cancer (CRC) screening procedures across the US. Methods: We compared prices of colonoscopy, flexible sigmoidoscopy, CT colonography, fecal occult blood test, fecal immunochemical test, and Cologuard across U.S. hospitals using the Turquoise dataset (N = 6,378). Psychiatric, rehabilitation, and pediatric hospitals were excluded. Prices in the top and bottom 1% were also excluded to minimize the effect of outliers. Prices were adjusted by the Medicare Geographic Price Index to account for regional variability. We then compared prices across several subgroups, including National Cancer Institute (NCI) designated hospitals, teaching hospitals, and investor owned hospitals. Significance was assessed using the Kruskal-Wallis test. To quantify price variability across insurance plans within a hospital, we defined the within-center-ratio as the 90th percentile rate at a hospital divided by the 10th percentile rate. To quantify variability across hospitals, the across-center-ratio was defined as the 90th percentile median rate across all hospitals divided by the 10th percentile median rate. Results: 1,460 hospitals reported commercial prices for colonoscopy with a median commercial price of $1,867 (IQR: $1,208 - $2,689). For colonoscopy, the within center ratio was 2.5 (IQR: 1.5 – 3.8) and the across-center ratio was 6.2. Prices for other procedures are provided in the table. Compared to non-investor owned hospitals, prices of colonoscopy ($2,082 vs $1,787, P <0.001) and flexible sigmoidoscopy ($2,022 vs $1,289, P <0.001) were significantly higher at investor owned hospitals. Furthermore, across investor classes, hospitals with >5% ownership from private equity firms had the highest median price for both colonoscopy ($2,898), and flexible sigmoidoscopy ($2,697). We did not find significant differences in price by NCI designation, academic teaching center affiliation, overall hospital mortality, overall hospital readmission rate, or urban/rural location. Conclusions: CRC screening procedure prices vary significantly both within and across hospitals. Private equity and other investor owned hospitals had significantly higher prices compared to non-investor owned hospitals.
Code type | Code description | Number of centers | Median commercial price, $ (IQR) | Within center ratio (IQR) | Across center ratio |
---|---|---|---|---|---|
45378 | Colonoscopy | 1,460 | 1,867 (1208 - 2689) | 2.5 (1.5 - 3.8) | 6.2 |
45330 | Flexible Sigmoidoscopy | 1,332 | 1,473 (823 - 2251) | 2.3 (1.4 - 3.9) | 15.9 |
82270 | Fecal occult blood test (guaiac) | 1,300 | 16 (7 - 32) | 3.2 (1.7 - 6.7) | 13.1 |
82274 | Fecal Immunochemical test | 1,185 | 41 (25 - 65) | 2.5 (1.6 - 4.3) | 5.5 |
74263 | CT colonography | 644 | 1,060 (675 - 1621) | 1.8 (1.1 - 3.3) | 5.8 |
81528 | Cologuard | 199 | 560 (509 - 1074) | 1.7 (1 - 2.6) | 3.4 |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Shai Friedland
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Derek W. Ebner
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Brendan Chia
2023 ASCO Gastrointestinal Cancers Symposium
First Author: Shai Friedland